Andrew Lo, Director at BridgeBio Pharma, Inc. (BBIO), sold 191,198 shares at $66.63 ($12.6M) on 2025-11-17, disclosed to the SEC on 2025-11-19.
Open-market sale of $12.6M BBIO by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $66.63 | 36,801 | $2.5M | 19.4% |
| 2 | $66.63 | 36,801 | $2.5M | 19.4% |
| 3 | $67.06 | 3,798 | $255K | 2.0% |
| 4 | $67.06 | 3,798 | $255K | 2.0% |
| 5 | $65.23 | 24,007 | $1.6M | 12.4% |
| 6 | $65.23 | 24,007 |
| $1.6M |
| 12.4% |
| 7 | $66.05 | 30,993 | $2.0M | 16.2% |
| 8 | $66.05 | 30,993 | $2.0M | 16.2% |
| Total | $66.11 avg | 191,198 | $12.6M | 100% |
| Filing → |
| UROV | BUY | 2019-06-19 | $303K | — | Filing → |
| UROV | BUY | 2019-06-14 | $355K | — | Filing → |
| UROV | BUY | 2019-06-11 | $292K | — | Filing → |